[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631202":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":35,"responsibleParty":52,"collaborators":21,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":21,"enrollmentInfo":66,"targetDuration":21,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":21,"overallStatus":38,"whyStopped":21,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Cincinnati","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Reduced Elective Nodal and CTV Dose","EXPERIMENTAL","Reduction in primary tumor and nodal CTV dose to 30 Gy.",[13,14],"Drug: Cisplatin","Radiation: Radiotherapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Cisplatin","Subjects will continue to receive standard systemic therapy of cisplatin during radiation therapy. Weekly SOC Cisplatin at a dose of 40mg\u002Fm2 or every 3-week dosing of 100mg\u002Fm2 will be administered per institutional guidelines during radiation therapy. The first cisplatin infusion should be initiated during the window from 24 hours before, to 48 hours after the first scheduled radiation treatment. Skipped cisplatin infusions should not be made up, and the last cisplatin infusion should be no later than 7 days after the last fraction of radiation.",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"RADIATION","Radiotherapy","Radiotherapy will involve a sequential boost approach. Treatment will begin with coverage of the primary site and elective nodal regions to 30 Gy, after which treatment volumes will be reduced to primary site and involved nodes only with PTV margin to 70 Gy.",[9],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"UCCC Clinical Trials Office","CONTACT","513-584-7698","cancer@uchealth.com",{"name":34,"role":30,"phone":21,"phoneExt":21,"email":21},"Sara Medek, MD",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Cincinnati Medical Center","RECRUITING","Cincinnati","Ohio","45219","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-84.51439,39.12711,{"lat":48,"lon":47},[51],{"name":34,"role":30,"phone":21,"phoneExt":21,"email":21},{"type":53,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"SPONSOR_INVESTIGATOR","Sara Medek","Principal Investigator","100631202","phase-2-reduced-elective-nodal-and-ctv-dose-for-hpv-oropharyngeal-squamous-cell-carcinoma-100631202",false,"NCT07497607","Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma","Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma (REDUCE-30)","REDUCE-30","Inclusion Criteria:\n\n1. Patients must have histologically or cytologically confirmed history of squamous cell carcinoma of the oropharynx (OPSCC) planned for definitive chemoradiation.\n2. Squamous cell carcinoma of the oropharynx (OPSCC) must be confirmed to be p16 positive based on immunohistochemical staining.\n3. OPSCC must be clinical stage T1-4N1-3M0 or T3-T4N0M0 as per AJCC volume 8.\n4. Patients must have measurable disease based on PET\u002FCT imaging completed within 45 days +\u002F- 1 week from date of eligibility confirmation.\n5. Age ≥18 years.\n6. ECOG performance status ≤2.\n7. Patients must be deemed eligible for planned SOC cisplatin per treating investigators and\u002For treating medical oncologist.\n8. Women of child-bearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.\n9. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* 1\\. Patients with metastatic or recurrent disease.\n\n  2\\. Carcinoma of the neck of unknown primary site origin (T0 is ineligible even if p16 is positive).\n\n  3\\. Prior radiotherapy resulting in overlap of radiation therapy fields.\n\n  4\\. Patients who are pregnant, nursing or intended to conceive or father children during the course of the study.\n\n  5\\. Patients with active autoimmune or connective tissue disease that require systemic treatment in the opinion of the Investigator.\n\n  6\\. Patients who are receiving any other investigational agents. Patients who have received other investigational agents previously who are no longer receiving these investigational agents may be eligible at the discretion of the Investigator.\n\n  7\\. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous or not preferable, in the opinion of the Investigator.","ALL","18 Years",{"count":67,"type":68},31,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","This is a single-arm, phase II study that is designed to investigate nodal and primary tumor CTV dose de-escalation (30 Gy) in HPV positive oropharyngeal cancer.",[74,75],"Oropharyngeal Squamous Cell Carcinoma","HPV Positive Oropharyngeal Squamous Cell Carcinoma","2026-05-13",{"date":78,"type":79},"2026-05-18","ACTUAL",{"date":76,"type":79},{"date":82,"type":68},"2036-05-13",{"name":54,"class":6},1]